Bunazosin

Bunazosin

Systematic (IUPAC) name
1-(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-1,4-diazepan-1-yl)butan-1-one
Clinical data
AHFS/Drugs.com	International Drug Names
Identifiers
CAS Number	80755-51-7
ATC code	none
PubChem	CID 2472
ChemSpider	2378
UNII	9UUW4V7G2H
ChEMBL	CHEMBL188185
Chemical data
Formula	C19H27N5O3
Molar mass	373.44 g/mol
SMILES CCCC(=O)N1CCCN(CC1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC
InChI InChI=1S/C19H27N5O3/c1-4-6-17(25)23-7-5-8-24(10-9-23)19-21-14-12-16(27-3)15(26-2)11-13(14)18(20)22-19/h11-12H,4-10H2,1-3H3,(H2,20,21,22) Key:RHLJLALHBZGAFM-UHFFFAOYSA-N
(verify)

Bunazosin (INN) is an alpha 1 antagonist. Bunazosin was initially developed to treat benign prostatic hyperplasia (BPH). It has been approved in Japan in a topical form to treat glaucoma. The mechanism of action is a reduction of aqueous outflow through the uveoscleral pathway resulting in lowering the intraocular pressure. It also may act to improve blood flow to the ocular nerve. Systemic Alpha-1 adrenergic receptor antagonists have been implicated in Intraoperative Floppy Iris Syndrome (IFIS). Bunazosin potentially could have the same effect but there has been no research to substantiate this as a risk for cataract surgery.